iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: https://pubmed.ncbi.nlm.nih.gov/26480023
Designed Amino Acid Feed in Improvement of Production and Quality Targets of a Therapeutic Monoclonal Antibody - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Oct 19;10(10):e0140597.
doi: 10.1371/journal.pone.0140597. eCollection 2015.

Designed Amino Acid Feed in Improvement of Production and Quality Targets of a Therapeutic Monoclonal Antibody

Fatemeh Torkashvand  1 , Behrouz Vaziri  1 , Shayan Maleknia  2 , Amir Heydari  3 , Manouchehr Vossoughi  3 , Fatemeh Davami  1 , Fereidoun Mahboudi  1
Affiliations

Designed Amino Acid Feed in Improvement of Production and Quality Targets of a Therapeutic Monoclonal Antibody

Fatemeh Torkashvand et al. PLoS One. .

Abstract

Cell culture feeds optimization is a critical step in process development of pharmaceutical recombinant protein production. Amino acids are the basic supplements of mammalian cell culture feeds with known effect on their growth promotion and productivity. In this study, we reported the implementation of the Plackett-Burman (PB) multifactorial design to screen the effects of amino acids on the growth promotion and productivity of a Chinese hamster ovary DG-44 (CHO-DG44) cell line producing bevacizumab. After this screening, the amino acid combinations were optimized by the response surface methodology (RSM) to determine the most effective concentration in feeds. Through this strategy, the final monoclonal antibody (mAb) titre was enhanced by 70%, compared to the control group. For this particular cell line, aspartic acid, glutamic acid, arginine and glycine had the highest positive effects on the final mAb titre. Simultaneously, the impact of the designed amino acid feed on some critical quality attributes of bevacizumab was examined in the group with highest productivity. The product was analysed for N-glycan profiles, charge variant distribution, and low molecular weight forms. The results showed that the target product quality has been improved using this feeding strategy. It was shown how this strategy could significantly diminish the time and number of experiments in identifying the most effective amino acids and related concentrations in target product enhancement. This model could be successfully applied to other components of culture media and feeds.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: Aryogen Biopharma Inc. provided support in the form of salaries for S. A. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.

Figures

Fig 1
Fig 1. Predicted values versus actual values plot for the final mAb titre, It helps we detect a value, or group of values, that are not easily predicted by the model.
The near 45 degree line of correlating plot shows the acceptable correlation between predicted and actual response values.
Fig 2
Fig 2. Representative charts of response surface.
Response surface shows the effects and interactions of Glu and Asp, Arg and Asp, Gly and Asp, Arg and Glu, Gly and Glu, Gly and Arg on the final mAb titre response. (For instance in part B, if Asp and Arg concentrations become less or more than the middle point (0), the response will reach the maximum amount. These changes should be the same for both amino acids. It means Asp and Arg should increase or decrease in one direction and if both of them decrease, the response will be better. Also in part C, if Asp and Gly concentrations increase toward +1, the response will reach the maximum amount.)
Fig 3
Fig 3. Comparison of final mAb titre in control and designed amino acid feed groups.
Fig 4
Fig 4. Glycoprofiling of bevacizumab in control and designed amino acid feed groups, glycan species abbreviations are as follow,G0: asialo, agalactose, biantennary complex (common core (Man3GlcNAc2) with terminal two GlcNAc residues), G0F: asialo, agalactose, biantennary complex, core substituted with fucose, G1: asialo, mono-galactosylated, biantennary complex, Man5: terminal two manose residues attached to the common core (Man3GlcNAc2), G1F/G1F’: asialo, mono-galactosylated, biantennary complex, core substituted with fucose, G2F: asialo, galactosylated, biantennary complex, core substituted with fucose.
Fig 5
Fig 5. Charge heterogeneity profiling of bevacizumab in control and designed amino acid feed groups.
Fig 6
Fig 6. Electropherograms of non-reduced bevacizumab in control and designed amino acid feed groups.
Fig 7
Fig 7. Electropherograms of reduced bevacizumab in control and designed amino acid feed groups, (LC: light chain, HC: heavy chain, NGHC: non glycosylated heavy chain).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kim JY, Kim YG, Lee GM. CHO cells in biotechnology for production of recombinant proteins: current state and further potential. Appl Microbiol Biotechnol. 93(3):917–30. 10.1007/s00253-011-3758-5 - DOI - PubMed
    1. Read EK, Bradley SA, Smitka TA, Agarabi CD, Lute SC, Brorson KA. Fermentanomics informed amino acid supplementation of an antibody producing mammalian cell culture. Biotechnol Prog. 2013;29(3):745–53. 10.1002/btpr.1728 - DOI - PubMed
    1. Gonzalez-Leal IJ, Carrillo-Cocom LM, Ramirez-Medrano A, Lopez-Pacheco F, Bulnes-Abundis D, Webb-Vargas Y, et al. Use of a Plackett-Burman statistical design to determine the effect of selected amino acids on monoclonal antibody production in CHO cells. Biotechnol Prog. 2011;27(6):1709–17. 10.1002/btpr.674 - DOI - PubMed
    1. Li F, Vijayasankaran N, Shen AY, Kiss R, Amanullah A. Cell culture processes for monoclonal antibody production. MAbs. 2010;2(5):466–79. . - PMC - PubMed
    1. Rita Costa A, Elisa Rodrigues M, Henriques M, Azeredo J, Oliveira R. Guidelines to cell engineering for monoclonal antibody production. Eur J Pharm Biopharm. 2009;74(2):127–38. 10.1016/j.ejpb.2009.10.002 - DOI - PubMed

Publication types

Grants and funding

This work was funded by Aryogen Biopharma Inc. The funder provided support in the form of salaries for S. A., but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of this author are articulated in the ‘author contributions’ section.